Product Images Rocuronium Bromide

This is a table indicating the success rate of Rocuronium Bromide in inducing good intubating conditions in patients of different age groups at different doses administered over 5 seconds. The success rate ranges from 86% to 100% depending upon the age group of the patient and the dose administered. Time to completion of intubation is also provided for each category.*

This is a table showing the administration of Rocuronium Bromide at various doses to patients in different age groups. The table provides the time taken for 280% block, time taken to reach maximum block, and clinical duration for each dose given. The age groups evaluated include adults (18-64 years), geriatrics (265 years), infants (3 months to 1 year), and pediatric (1 to 12 years).*

This is a chart showing pharmacokinetic parameters in different age ranges (birth to 28 days, 28 days to 3 months, 3 months to 2 years, and 2 to <17 years) for a particular medication. The parameters include clearance (CL), volume of distribution (O), and half-life (1/2 B).*

This is a table presenting the recommended dose and time to maximum block and reappearance T3 for Rocuronium Bromide in neonates, infants, toddlers, children, and adolescents. The dose is given in mg/kg and time is given in minutes. The data show that the recommended dose and time varies depending on the age of the patient. The table provides useful information for healthcare professionals administering Rocuronium Bromide to patients in different age groups.*

The figure displays the relationship between the initial dose of Rocuronium Bromide and the duration of clinical effect categorized by age group. The median, 25th and 75th percentile, and individual values are presented for each age group: 3 months to 1 year, 1 to 12 years, 18 to 64 years, and over 65 years. The initial dose is measured in mg/kg.*

This text describes PK parameters in adults and geriatrics, with a range of ages between 27-58 years old and those 65 years old and older. It includes clearance, volume of distribution, steady-state, and half-life of elimination. The values for each parameter are provided in parentheses.*

This is a table showing PK parameters for patients with normal renal function, renal transplant, and hepatic dysfunction. The values displayed are clearance, volume of distribution at steady state, and half-life of elimination for patients with hepatic dysfunction compared to those with normal renal function and those who have received a renal transplant.*

This text shows pharmacokinetic parameters of a drug for patients in different age ranges, including its clearance, volume of distribution, and half-life of elimination. The age ranges are divided into three groups: 3 to 12 months, 1 to less than 3 years, and 3 to 8 years. These parameters are important in determining the appropriate dosage of the drug for each age group.*

This table shows the infusion delivery rate in mL/hr according to the patient weight and the drug delivery rate expressed in mcg/kg/min. The infusion delivery rate varies depending on the patients' weight and the desired drug delivery rate in micrograms per kilogram per minute.*

This table shows the recommended drug delivery rates (in mL/hr) for patients of different weights (in Ibs) at different drug delivery rates (in mcg/kg/min). The drug dosage varies according to the patient's weight and the rate of delivery prescribed by the physician. These guidelines help doctors to determine the appropriate drug dosage and delivery rate to ensure the safety and effectiveness of the treatment.*

This table shows the Drug Delivery Rate (mcg/kg/min) based on the Patient Weight (lbs) and Infusion Delivery Rate (mL/hr). The table is divided into different weight categories ranging from 4 to 100 Ibs, and corresponding to each weight, the recommended drug delivery rate and infusion delivery rate are given in the table.*

This document provides important information about dosing and administration of a medication, including specific dosages for different patient populations. It also includes warnings about the risk of medication errors that could result in death, as well as the risk of residual paralysis. This information was last updated on multiple dates in 2017 and 2018.*

Hospira is a pharmaceutical company.*

This is a product that is distributed by HF Acquisition Co., LLC located in Mukilteo, WA 98275. The product's name or purpose is not available from the given text. It provides some identification numbers.*

This is a pharmaceutical product that is distributed by HF Acquisition Co., LLC in Mukilteo, WA. The manufacturer's package insert should be consulted before use. Other information such as a product name or purpose is not available.*

This is a product label for Rocur Bromide Injection. The GS1 Databar Limited barcode contains the product code. The rest of the text is not readable or coherent.*